Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 37

References for PMC Articles for PubMed (Select 19299471)


Class-sparing regimens for initial treatment of HIV-1 infection.

Riddler SA, Haubrich R, DiRienzo AG, Peeples L, Powderly WG, Klingman KL, Garren KW, George T, Rooney JF, Brizz B, Lalloo UG, Murphy RL, Swindells S, Havlir D, Mellors JW; AIDS Clinical Trials Group Study A5142 Team.

N Engl J Med. 2008 May 15;358(20):2095-106. doi: 10.1056/NEJMoa074609.


The impact of reducing stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patients.

Milinkovic A, Martinez E, López S, de Lazzari E, Miró O, Vidal S, Blanco JL, Garrabou G, Laguno M, Arnaiz JA, Leon A, Larrousse M, Lonca M, Mallolas J, Gatell JM.

Antivir Ther. 2007;12(3):407-15.


Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS clinical trial group 5125s).

Tebas P, Zhang J, Yarasheski K, Evans S, Fischl MA, Shevitz A, Feinberg J, Collier AC, Shikuma C, Brizz B, Sattler F; AIDS Clinical Trials Group (ACTG).

J Acquir Immune Defic Syndr. 2007 Jun 1;45(2):193-200.


A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy.

Moyle GJ, Sabin CA, Cartledge J, Johnson M, Wilkins E, Churchill D, Hay P, Fakoya A, Murphy M, Scullard G, Leen C, Reilly G; RAVE (Randomized Abacavir versus Viread Evaluation) Group UK.

AIDS. 2006 Oct 24;20(16):2043-50.


Changes in body composition and mitochondrial nucleic acid content in patients switched from failed nucleoside analogue therapy to ritonavir-boosted indinavir and efavirenz.

Boyd MA, Carr A, Ruxrungtham K, Srasuebkul P, Bien D, Law M, Wangsuphachart S, Krisanachinda A, Lerdlum S, Lange JM, Phanuphak P, Cooper DA, Reiss P.

J Infect Dis. 2006 Sep 1;194(5):642-50. Epub 2006 Jul 18. Erratum in: J Infect Dis. 2006 Sep 15;194(6):870. Dosage error in article text.


Pronounced lipoatrophy in HIV-infected men receiving HAART for more than 6 years compared with the background population.

Hansen AB, Lindegaard B, Obel N, Andersen O, Nielsen H, Gerstoft J.

HIV Med. 2006 Jan;7(1):38-45.


Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides.

Dubé MP, Parker RA, Tebas P, Grinspoon SK, Zackin RA, Robbins GK, Roubenoff R, Shafer RW, Wininger DA, Meyer WA 3rd, Snyder SW, Mulligan K.

AIDS. 2005 Nov 4;19(16):1807-18.


Fat distribution in men with HIV infection.

Bacchetti P, Gripshover B, Grunfeld C, Heymsfield S, McCreath H, Osmond D, Saag M, Scherzer R, Shlipak M, Tien P; Study of Fat Redistribution and Metabolic Change in HIV Infection (FRAM).

J Acquir Immune Defic Syndr. 2005 Oct 1;40(2):121-31.


Uridine in the prevention and treatment of NRTI-related mitochondrial toxicity.

Walker UA, Venhoff N.

Antivir Ther. 2005;10 Suppl 2:M117-23. Review.


Soft tissue augmentation using sculptra.

Humble G, Mest D.

Facial Plast Surg. 2004 May;20(2):157-63.


Changes in mitochondrial DNA in peripheral blood mononuclear cells from HIV-infected patients with lipoatrophy randomized to receive abacavir.

Hoy JF, Gahan ME, Carr A, Smith D, Lewin SR, Wesselingh S, Cooper DA.

J Infect Dis. 2004 Aug 15;190(4):688-92. Epub 2004 Jul 12.


Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.

Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, Coakley DF, Lu B, Toole JJ, Cheng AK; 903 Study Group.

JAMA. 2004 Jul 14;292(2):191-201.


Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study.

Martin A, Smith DE, Carr A, Ringland C, Amin J, Emery S, Hoy J, Workman C, Doong N, Freund J, Cooper DA; Mitochondrial Toxicity Study Group.

AIDS. 2004 Apr 30;18(7):1029-36.


A randomized open-label study of immediate versus delayed polylactic acid injections for the cosmetic management of facial lipoatrophy in persons with HIV infection.

Moyle GJ, Lysakova L, Brown S, Sibtain N, Healy J, Priest C, Mandalia S, Barton SE.

HIV Med. 2004 Mar;5(2):82-7.


Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study.

McComsey GA, Ward DJ, Hessenthaler SM, Sension MG, Shalit P, Lonergan JT, Fisher RL, Williams VC, Hernandez JE; Trial to Assess the Regression of Hyperlactatemia and to Evaluate the Regression of Established Lipodystrophy in HIV-1-Positive Subjects (TARHEEL; ESS40010) Study Team.

Clin Infect Dis. 2004 Jan 15;38(2):263-70. Epub 2003 Dec 18.


Polylactic acid implants (New-Fill) to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA.

Valantin MA, Aubron-Olivier C, Ghosn J, Laglenne E, Pauchard M, Schoen H, Bousquet R, Katz P, Costagliola D, Katlama C.

AIDS. 2003 Nov 21;17(17):2471-7.


HIV lipodystrophy: prevalence, severity and correlates of risk in Australia.

Miller J, Carr A, Emery S, Law M, Mallal S, Baker D, Smith D, Kaldor J, Cooper DA.

HIV Med. 2003 Jul;4(3):293-301.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk